[Asia Economy Reporter Hyunseok Yoo] Gyeongnam Biopharma and Biowithus announced on the 4th that they have completed the joint development of a COVID-19 diagnostic reagent including variants.
In April of last year, Gyeongnam Biopharma signed a contract with Biowithus for the joint development of diagnostic test reagents for variant COVID-19 and conducted related research.
Recently, as variant viruses with much higher transmissibility than the existing COVID-19 have been discovered mainly in South Africa, Brazil, the United Kingdom, and Germany, Gyeongnam Biopharma proceeded with the goal of producing COVID-19 diagnostic reagents and diagnostic kits.
A company official stated, "We will do our best to prepare for the post-COVID era through the development of diagnostic test reagents with improved accuracy."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
